Magenta Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
100 Technology Sq Fl 5, Cambridge, Massa...Website
www.magentatx.comRevenue
$15.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Magenta Therapeutics
Magenta Therapeutics is focused in developing medicines to make cures possible for more patients with blood cancers, genetic diseases and autoimmune diseases.Explore more
Magenta Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Magenta Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Magenta Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Magenta Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Magenta Therapeutics
Magenta Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Magenta Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Magenta Therapeutics has new funding data
Product Launch: Get notified when Magenta Therapeutics launches new products
Check out if Magenta Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Magenta Therapeutics
Find 3 more new buyers
Compare Similar Companies to Magenta Therapeutics
Compare insights from companies similar to Magenta Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Magenta Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Magenta Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Magenta Therapeutics.
Magenta Therapeutics financials insights
Gather financial insights about Magenta Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series A
$48.5M
2017
Series B
$50M
2018
Series C
$52M
Stock Offering
$100M
2020
Stock Offering
$60M
2021
Stock Offering
$86.4M
Magenta Therapeutics Tech Stack
A closer look at the technologies used by Magenta Therapeutics
Most Recent Scoops
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Magenta Therapeutics News & Media
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Magenta Therapeutics, Inc. (NasdaqGM: MGTA) with Dianthus Therapeutics, Inc. pursuant to which Magenta shareholders are expected to own approximately 21.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervaluesMagenta Therapeutics and Dianthus Therapeutics to Merge
CAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) — Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics, Inc., a privately-held, clinical-stage biotechnology company dedicated... Read More The post Magenta Therapeutics and Dianthus Therapeutics to Merge appeared first on citybiz.Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death
Magenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, currently in Phase 1 trial. Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics Inc and trade on the Nasdaq under the ticker symbol DNTH. Magenta's stockholders will own about 2SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Magenta Therapeutics, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - May 3, 2023) - Rigrodsky Law, P.A. is investigating Magenta Therapeutics, Inc. ("Magenta") (NASDAQ: MGTA) regarding possible breaches of fiduciary duties and other violations of law related to Magenta's agreement to merge with Dianthus Therapeutics, Inc.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-magenta-therapeutics-inc.To contact Seth D. Rigrodsky or Gina M. Serra cost free, call or text (302) 295-5310 or
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Magenta Therapeutics
Sign Up For FreeTo access detailed company insights
Magenta Therapeutics is focused in developing medicines to make cures possible for more patients with blood cancers, genetic diseases and autoimmune diseases.... Read More
